1. Home
  2. COLL vs FSLY Comparison

COLL vs FSLY Comparison

Compare COLL & FSLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • FSLY
  • Stock Information
  • Founded
  • COLL 2002
  • FSLY 2011
  • Country
  • COLL United States
  • FSLY United States
  • Employees
  • COLL N/A
  • FSLY N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • FSLY Computer Software: Prepackaged Software
  • Sector
  • COLL Health Care
  • FSLY Technology
  • Exchange
  • COLL Nasdaq
  • FSLY Nasdaq
  • Market Cap
  • COLL 1.1B
  • FSLY 1.0B
  • IPO Year
  • COLL 2015
  • FSLY 2019
  • Fundamental
  • Price
  • COLL $29.58
  • FSLY $6.42
  • Analyst Decision
  • COLL Strong Buy
  • FSLY Hold
  • Analyst Count
  • COLL 6
  • FSLY 9
  • Target Price
  • COLL $42.00
  • FSLY $7.94
  • AVG Volume (30 Days)
  • COLL 440.1K
  • FSLY 3.0M
  • Earning Date
  • COLL 11-07-2024
  • FSLY 11-06-2024
  • Dividend Yield
  • COLL N/A
  • FSLY N/A
  • EPS Growth
  • COLL 757.11
  • FSLY N/A
  • EPS
  • COLL 2.16
  • FSLY N/A
  • Revenue
  • COLL $599,245,000.00
  • FSLY $540,874,000.00
  • Revenue This Year
  • COLL $13.02
  • FSLY $9.08
  • Revenue Next Year
  • COLL $18.01
  • FSLY $5.57
  • P/E Ratio
  • COLL $13.68
  • FSLY N/A
  • Revenue Growth
  • COLL 9.62
  • FSLY 10.94
  • 52 Week Low
  • COLL $25.07
  • FSLY $5.52
  • 52 Week High
  • COLL $42.29
  • FSLY $25.87
  • Technical
  • Relative Strength Index (RSI)
  • COLL 26.96
  • FSLY 41.16
  • Support Level
  • COLL $29.69
  • FSLY $7.04
  • Resistance Level
  • COLL $35.62
  • FSLY $7.59
  • Average True Range (ATR)
  • COLL 1.41
  • FSLY 0.42
  • MACD
  • COLL -0.39
  • FSLY -0.08
  • Stochastic Oscillator
  • COLL 6.36
  • FSLY 1.79

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About FSLY Fastly Inc.

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2023.

Share on Social Networks: